Clinical profile of roflumilast;Perfil clínico del roflumilast

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.10, 2010, Pages 25-32

  Izquierdo Alonso, José Luis ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Chronic bronchitis; COPD; Roflumilast

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; ROFLUMILAST;

ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; LUNG FUNCTION; MORBIDITY; QUALITY OF LIFE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; BRONCHITIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; CYCLOPROPANES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MICE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79851478852     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70053-3     Document Type: Article

References (29)

1. Committee for Medicinal Products for Human Use. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). London, 19 May 1999. EMEA/CPMP/EWP/ 562/98.
2. FDA: Draft Guidance for Industry: Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment, November 2007.
3. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbroker D., Bethke T.D. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
4. Soler-Cataluña J., Martínez-García M.A., Sánchez L., Tordera M., Sánchez P. Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med 2009, 103:692-699.
5. Spencer S., Calverley P.MA., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702.
6. Calverley P.M., Sánchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161.
7. Calverley P.M., Martínez F.J., Goehring U.M., Rennard S.I. Defining patient populations in COPD: experience with roflumilast. 7th International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD7) 2010.
8. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., Martínez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009, 374:685-694.
9. Fabbri L.M., Calverley P., Izquierdo J.L., Bundschuh D., Brose M., Martínez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomised clinical trials. Lancet 2009, 374:695-703.
10. Hanania N.A., Brose M., Larsson T., Rabe KF. Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months. Am J Respir Crit Care Med 2010, 181:A4435.
11. Bateman E.D., Calverley P.M., Fabbri L.M., Rabe K.F., Rennard S.I., Martínez F.J., et al. Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-mont studies. European Respiratory Society Annual Congress 2010 2010.
12. Izquierdo JL, Aparicio J. Roflumilast for COPD. Drugs today. (En prensa.).
13. Gross N.J., Giembycz M.A., Rennard S.I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010, 7:141-153.
14. Burgel P.R., Nesme-Meyer P., Chanez P., Caillaud P., Carré P., Pérez T., et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009, 135:975-982.
15. Saetta M., Baraldo S., Corbino L., Turato G., Braccioni F., Rea F., et al. CD8+ ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:711-717.
16. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
17. Boswell-Smith V., Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2007, 2:121-129.
18. Hatzelmann A., Morcillo E.J., Lungarella G., Adnot S., Sanjar S., Beume R., et al. The preclinical pharmacology of roflumilast: A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
19. Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease. Eur Respir J 2003, 21:68-73.
20. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003, 361:449-456.
21. Calverley P., Pauwels R.A., Jones P.W., Anderson J.A., Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:209-218.
22. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
23. McQuay H.J., Moore R.A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997, 126:712-720.
24. Izquierdo J.L., MacNee W., Biermann E., Goehring U.M., McIvor R.A. The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol. the European Respiratory Society Annual Congress 2009 2009.
25. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007, 146:545-555.
26. Paggiaro P.L., Foden A.P. Improvements in breathlessness in patients with chronic obstructive pulmonary disease treated with roflumilast and tiotropium. Chest Meeting Abstracts 2009, 136:3s.
27. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
28. Loppow D., Schleiss M.B., Kanniess F., Taube C., Jorres R.A., Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001, 95:115-121.
29. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.